PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: TCG Lifesciences Ltd

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

TCGLS Completes Key Milestones on Delivery of Pre-clinical Drug Candidates to Endo Pharma - TCG Lifesciences Limited (TCGLS) announced the achievement of two distinct milestones in their ongoing drug discovery partnership with Endo Pharmaceuticals. TCGLS will receive undisclosed success fees against these milestones - TCGLS.com
TCGLS Completes Key Milestones on Delivery of Pre-clinical Drug Candidates to Endo Pharma

 

NewswireToday - /newswire/ - Kolkata, West Bengal, India, 2012/01/30 - TCG Lifesciences Limited (TCGLS) announced the achievement of two distinct milestones in their ongoing drug discovery partnership with Endo Pharmaceuticals. TCGLS will receive undisclosed success fees against these milestones - TCGLS.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

In the first of two fully integrated discovery programs with Endo aimed at identifying novel small molecule drug candidates for an unmet medical need, TCGLS has successfully delivered a pre-clinical development candidate. Both partners contributed to the discovery program’s architecture, including biological and in-vivo assay design, screening decision tree and medicinal chemistry design. Working closely with Endo scientists, the TCGLS collaboration team members conducted all aspects of laboratory research for the program involving medicinal chemistry, in vitro biology, ADME, animal pharmacology and early toxicology capabilities.

Two lead molecules resulting from this collaboration have been selected by Endo for cGMP manufacturing and GLP-toxicology studies.

In the second of two fully integrated discovery programs with Endo, initiated in 2011, TCGLS has also achieved a discovery milestone. Under this program, TCGLS has designed and delivered novel fast-follower hit structures well within collaboration timelines. This multi-year, three-stage project aims to identify potent in-vivo active novel blockers of an undisclosed target for eventual clinical development.

Commenting on these developments, Mr. Swapan Bhattacharya, Managing Director, TCG Lifesciences, said: “These successes demonstrate the progress TCGLS has made in driving innovation and the commitment of TCGLS scientists to collaborate with partners to deliver novel molecules.” Dr. Ashis Saha, VP Discovery Research, TCG Lifesciences, remarked “The dedication, passion, insight and extraordinary effort of our scientists contributed to the achievement of these milestones. Several team members are co-inventors in patent applications covering composition of the lead molecules which is a testament to the talent and creativity of our team members. Dr. Sandeep Gupta, Senior Vice President, Discovery & Early Development, Research and Development at Endo Pharmaceuticals, said,“This is a proud moment for the Endo - TCGLS collaboration. Achievement of these milestones is a testimony to the great team effort and a strong collaborative spirit demonstrated by both sides. We look forward to achieving many more milestones in our programs and to developing novel treatment options for the benefit of patients. ”

Contact for TCG Lifesciences:
Corporate Affairs Department
M: 91 9810730653 / E: sandeep.gupta[.]tcgls.com.

About TCG Lifesciences Limited
TCG Lifesciences Limited (tcgls.com) is a leading Contract Research Services, clinical research, and laboratory informatics company with operations in India, Europe, Japan, Australia and the United States. It is part of The Chatterjee Group, a global investment conglomerate headquartered in New York. TCGLS collaborates to service the multi-disciplinary research efforts of global pharmaceutical and biotechnology companies through its three units: Chembiotek (Discovery Research), Clininvent (Clinical Research Solutions), and LabVantage (Enterprise Informatics). It has trust based relationships with a majority of the global pharmaceutical companies. The relationships span from specific solutions and sourcing services to integrated projects across multiple domains to complete translational research programs in the drug discovery and development space.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: TCG Lifesciences Ltd

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


TCGLS Completes Key Milestones on Delivery of Pre-clinical Drug Candidates to Endo Pharma

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: TCGLS.com 
+91-33-2367 3151 tanuja.thapliyal[.]tcgls.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any TCG Lifesciences Ltd securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From TCG Lifesciences Ltd / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

Frost & Sullivan Commends Nemaura for Developing Superior Transdermal Drug Delivery Technology Platforms, the Memspatch and Micropatch
Greenphire Sponsors Second Annual Clinical Trial Agreements, Investigator Payments and Fair Market Value Meeting
Genentech’s Gazyva Helped People with Previously Untreated Follicular Lymphoma Live Significantly Longer
BD Announces Adoption of Windows 10 ‘Internet of Things’ for the Pyxis™ ES System
Greenphire Named to Deloitte 2016 Technology Fast 500™
Genentech Showcases New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
BD Collaborates with JDRF to Focus on Extended Wear Innovations for Insulin Infusion Delivery
BD Launches First Syringe Designed for Use with Humulin® R U-500 Insulin
MDxHealth Announces Unique CPT Code Awarded for ConfirmMDx from the American Medical Association
BD MAX™ Vaginal Panel Receives FDA Market Authorization to Detect Most Common Causes of Vaginal Infections
Greenphire Receives EU-US Privacy Shield Certification
The 2016 Georges Mathé Prize Recognizes Research on the Immunological Determinants of the Response to Breast Cancer Treatment
MDxHealth Announces Agreement with HIFU CLINIC Prostate Cancer Center for Distribution of SelectMDx in Poland
First Patient in Malaysia Receives TheraSphere™ Radioembolisation Therapy
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) Prefilled Syringe

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  Triggr & Bloom

Visit  BizJobs.com





 
  ©2016 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)